TZIELD (teplizumab) and the Risk of Viral Reactivation
Critical priority
The issue
New safety information - Adverse reaction - Product safety
Affected product
TZIELD, teplizumab for injection, 2 mg per 2 mL (1 mg/mL) for intravenous infusion
Where it was sold
Canada (national)Reported in the official notice — confirm there.
Issued by
Health Canada — Marketed health products
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.